TRACON Pharmaceuticals Inc (TCON): TCON obtains SPA for TRC105 in angiosarc...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Re: None

Tuesday, 01/03/2017 8:57:30 AM

Tuesday, January 03, 2017 8:57:30 AM

TCON obtains SPA for TRC105 in angiosarcoma: #msg-127577935.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Keep Last Read

Replies (1) Next 10 Prev Next

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/30/2024 09:05:03 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/30/2024 09:00:03 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 09:00:18 PM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/09/2024 09:00:03 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 08:52:07 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 09:00:11 PM

InvestorsHub NewsWire

FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM

FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM

Only $200 per official company press release!